Dachaigh › Aillse a' bhroilleach › Arizona › Phoenix
Sgrùdaidhean clionaigeach Aillse a' bhroilleach ann an Phoenix, AZ
Tha 25 sgrùdaidhean airson Aillse a' bhroilleach a’ lorg phàirtichean aig làraichean ann agus timcheall air Phoenix (taobh a-staigh mu 30 mìle). Fosglaidh sgrùdadh gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.
Teacsa sgrùdaidh oifigeil (Beurla)
A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
- Cancer Center at Saint Joseph's, Phoenix
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
A’ fastadhÌre 2
- Mayo Clinic Hospital, Phoenix
PRE-ISPY Phase I/II Oncology Platform Program
A’ fastadhÌre 1/2
- Mayo Clinic Comprehensive Cancer Center, Phoenix
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
A’ fastadhÌre 3
- Mayo Clinic Cancer Center ( Site 0034), Phoenix
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
A’ fastadhÌre 3
- Ironwood Cancer & Research Centers, Phoenix
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
A’ fastadhÌre 2
- Mayo Clinic Building-Phoenix, Phoenix
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
A’ fastadh
- Mayo Clinic Arizona, Phoenix
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
A’ fastadhÌre 3
- Mayo Clinic in Arizona - Phoenix, Phoenix
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
A’ fastadhÌre 2
- Mayo Clinic in Arizona - Phoenix, Phoenix
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
A’ fastadhÌre 3
- Banner University Medical Center - Phoenix Campus (Banner Good Samaritan Medical Center), Phoenix
Breast Cancer, Reasoning, and Activity Intervention
A’ fastadh
- Mayo Clinic in Arizona, Phoenix
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
A’ fastadhÌre 3
- The Dignity Health Cancer Institute, Phoenix
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
A’ fastadhÌre 3
- Cancer Center at Saint Joseph's, Phoenix
- Mayo Clinic Hospital in Arizona, Phoenix
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
A’ fastadhÌre 3
- Mayo Clinic-Comprehensive Cancer Center-Breast Clinic, Phoenix
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
A’ fastadhÌre 3
- Mayo Clinic Hospital in Arizona, Phoenix
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
A’ fastadhÌre 1/2
- USOR HonorHealth, Phoenix
E-Mindfulness Approaches for Living After Breast Cancer
A’ fastadhÌre 3
- Mayo Clinic Hospital in Arizona, Phoenix
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
A’ fastadhÌre 1/2
- Mayo Clinic Comprehensive Cancer Center, Phoenix
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
A’ fastadhÌre 3
- Ironwood Cancer & Research Centers, Phoenix
The RolE of Prolonged Nightly faSTing to Improve Sleep and cOgnition in bREast Cancer Survivors
A’ fastadh
- Arizona State University, Phoenix
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
A’ fastadhÌre 3
- Cancer Center at Saint Joseph's, Phoenix
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
A’ fastadhÌre 1/2
- Mayo Clinic, Phoenix
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
A’ fastadhSgrùdadh amharc
- Cancer Center at Saint Joseph's, Phoenix
Clinical Validation of Early Detection Blood Test for Universal Large-scale Breast Cancer Screening
A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
- Vincere Cancer Center, Phoenix
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
A’ fastadhSgrùdadh amharc
- Arizona Oncology Associates, PC, Phoenix
Sgrùdaidhean Aillse a' bhroilleach ann am bailtean eile
- New York City, NY134 sgrùdaidhean
- Houston, TX126 sgrùdaidhean
- Boston, MA111 sgrùdaidhean
- Nashville, TN80 sgrùdaidhean
- Los Angeles, CA72 sgrùdaidhean
- Edison, NJ68 sgrùdaidhean
- St. Louis, MO64 sgrùdaidhean
- Durham, NC63 sgrùdaidhean
- Queens, NY63 sgrùdaidhean
- Chicago, IL58 sgrùdaidhean
- Philadelphia, PA56 sgrùdaidhean
- Dallas, TX55 sgrùdaidhean
Sgrùdaidhean eile ann an Phoenix
- Aillse colorectal25 sgrùdaidhean
- Obesity22 sgrùdaidhean
- Aillse Sgamhain Neo-chealla-beag20 sgrùdaidhean
- Ailse metastatach20 sgrùdaidhean
- Fàilligeadh a' Chridhe18 sgrùdaidhean
- Aillse Prostata17 sgrùdaidhean
- Aillse (gach seòrsa)17 sgrùdaidhean
- Myeloma iomaill16 sgrùdaidhean
- Cancer Pancreatic16 sgrùdaidhean
- Galarachd Cardiovasculach16 sgrùdaidhean
- Galar Alzheimer15 sgrùdaidhean
- Ro-throm15 sgrùdaidhean
Bho ClinicalTrials.gov, dàta air a thogail 5 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.